Kite catch­es the in­side track on the last leg of a race to the fin­ish line with No­var­tis on a CAR-T first

The race be­tween No­var­tis $NVS and Kite $KITE to win the first FDA ap­proval of a CAR-T for can­cer is now in the fi­nal stretch, and Kite just short­ened its dis­tance to the fin­ish line.

The biotech an­nounced this morn­ing that the FDA is pro­vid­ing a pri­or­i­ty re­view for their drug KTE-C19 (axi­cab­ta­gene ciloleu­cel), which will cut the time it takes for reg­u­la­tors to com­plete their ex­am­i­na­tion from 10 months down to 6. The FDA’s PDU­FA date is No­vem­ber 29.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.